Pfizer Short-Term Investments increased by 1004.1% to $12.45B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 35.9%, from $19.43B to $12.45B. Over 5 years (FY 2020 to FY 2025), Short-Term Investments shows an upward trend with a 3.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Higher levels indicate strong liquidity and significant 'dry powder' for acquisitions or R&D, while lower levels might suggest cash is being deployed into long-term projects or shareholder returns.
Highly liquid assets and marketable securities that are expected to be converted into cash within one year. For technolo...
Commonly compared against other cash-rich technology peers to assess capital preservation strategies and short-term solvency.
short_term_investments| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.02B | $2.48B | $29.13B | $1.33B | $1.53B | $2.50B | $22.32B | $523.00M | $423.00M | $1.59B | $9.84B | $510.00M | $673.00M | $591.00M | $19.43B | $679.00M | $399.00M | $1.13B | $12.45B |
| QoQ Change | — | -18.0% | >999% | -95.4% | +15.0% | +63.1% | +794.4% | -97.7% | -19.1% | +276.6% | +517.5% | -94.8% | +32.0% | -12.2% | >999% | -96.5% | -41.2% | +182.7% | >999% |
| YoY Change | — | — | — | — | -49.3% | +0.8% | -23.4% | -60.7% | -72.4% | -36.2% | -55.9% | -2.5% | +59.1% | -62.9% | +97.6% | +33.1% | -40.7% | +90.9% | -35.9% |
We use cookies for analytics. See our Privacy and Cookie Policy.